Moderna reports Q3 amid valuation debate and cancer vaccine results
FROM THE WIRE · SEEKINGALPHA.COM
[Coronavirus, flu or measles vaccine vial with syringe on pink background . Flu vaccine for children] Irina Shatilova Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) will report its third-quarter earnings on November 5, after the closing bell, amid heated discussions…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralQuarterly results of a notable biotech stock, with expected loss and revenue decline.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Moderna will report third-quarter earnings on November 5 after the close.
- 02Analysts expect a loss of $1.35 per share on revenue of $890.22M.
- 03Expected revenue is down 12.7% year over year.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Moderna, Inc.240.84 USD+0.85%today -6.79%Neutral Merck & Co., Inc.148.50 USD-0.58%today -1.24%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets